Birdwatch Note
2024-11-03 17:23:23 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
ベトナムで行われたフェーズ3b試験ではワクチン接種者5人、プラセボ16人、計21人が死亡しています ワクチン接種者の5人のうち１名プラセボ投与者16人のうち9名は死因がコロナ感染であると報告されています プラセボ群のほうがワクチン群よりも死亡していること有害事象についても精査されている点に注意が必要です また、このことは論文として報告されており、論文は薬事審議にも活用されています 初めて明かされた真実ではないことに注意が必要ですhttps://www.nature.com/articles/s41467-024-47905-1 Meiji Seika ファルマ代表取締役社長の小林氏が会見を開き科学的根拠のない情報に対し提訴する考えを示しました https://medical.nikkeibp.co.jp/leaf/mem/pub/report/t344/202410/586081.html
Written by 7A9FF9E0AC22B46DA9E28988C69E88AB84BA7BDC51EFDA1B44D021A9037A2442
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1853106568029721048
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1853125836188299433
- noteId - 1853125836188299433
- participantId -
- noteAuthorParticipantId - 7A9FF9E0AC22B46DA9E28988C69E88AB84BA7BDC51EFDA1B44D021A9037A2442 Participant Details
- createdAtMillis - 1730654603417
- tweetId - 1853106568029721048
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 1
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- ベトナムで行われたフェーズ3b試験ではワクチン接種者5人、プラセボ16人、計21人が死亡しています ワクチン接種者の5人のうち１名プラセボ投与者16人のうち9名は死因がコロナ感染であると報告されています プラセボ群のほうがワクチン群よりも死亡していること有害事象についても精査されている点に注意が必要です また、このことは論文として報告されており、論文は薬事審議にも活用されています 初めて明かされた真実ではないことに注意が必要ですhttps://www.nature.com/articles/s41467-024-47905-1 Meiji Seika ファルマ代表取締役社長の小林氏が会見を開き科学的根拠のない情報に対し提訴する考えを示しました https://medical.nikkeibp.co.jp/leaf/mem/pub/report/t344/202410/586081.html
Note Ratings
| rated at | rated by | |
| 2024-11-04 15:10:38 -0600 | Rating Details | |
| 2024-11-04 08:15:12 -0600 | Rating Details | |
| 2024-11-04 03:57:32 -0600 | Rating Details | |
| 2024-11-04 02:10:21 -0600 | Rating Details | |
| 2024-11-04 01:50:12 -0600 | Rating Details | |
| 2024-11-04 00:30:50 -0600 | Rating Details | |
| 2024-11-04 00:28:46 -0600 | Rating Details | |
| 2024-11-04 00:28:46 -0600 | Rating Details | |
| 2024-11-04 00:23:48 -0600 | Rating Details | |
| 2024-11-04 00:21:36 -0600 | Rating Details | |
| 2024-11-04 00:06:45 -0600 | Rating Details | |
| 2024-11-03 22:53:00 -0600 | Rating Details | |
| 2024-11-03 22:51:40 -0600 | Rating Details | |
| 2024-11-03 22:37:44 -0600 | Rating Details | |
| 2024-11-03 22:30:22 -0600 | Rating Details | |
| 2024-11-03 22:08:26 -0600 | Rating Details | |
| 2024-11-03 21:21:20 -0600 | Rating Details | |
| 2024-11-03 21:02:36 -0600 | Rating Details | |
| 2024-11-03 20:58:36 -0600 | Rating Details | |
| 2024-11-03 20:38:17 -0600 | Rating Details | |
| 2024-11-03 20:35:17 -0600 | Rating Details | |
| 2024-11-03 20:27:30 -0600 | Rating Details | |
| 2024-11-03 20:00:27 -0600 | Rating Details | |
| 2024-11-03 19:07:42 -0600 | Rating Details | |
| 2024-11-03 18:15:06 -0600 | Rating Details | |
| 2024-11-03 17:02:54 -0600 | Rating Details | |
| 2024-11-03 16:52:17 -0600 | Rating Details | |
| 2024-11-03 11:32:50 -0600 | Rating Details | |
| 2024-11-05 04:05:38 -0600 | Rating Details | |
| 2024-11-04 01:32:13 -0600 | Rating Details | |
| 2024-11-03 21:50:57 -0600 | Rating Details | |
| 2024-11-03 21:28:46 -0600 | Rating Details | |
| 2024-11-03 19:13:59 -0600 | Rating Details | |
| 2024-11-03 18:51:08 -0600 | Rating Details | |
| 2024-11-03 18:36:28 -0600 | Rating Details | |
| 2024-11-03 16:35:43 -0600 | Rating Details | |
| 2024-11-03 15:57:24 -0600 | Rating Details | |
| 2024-11-03 15:41:15 -0600 | Rating Details | |
| 2024-11-03 13:40:13 -0600 | Rating Details | |
| 2024-11-04 18:47:17 -0600 | Rating Details | |
| 2024-11-04 09:38:38 -0600 | Rating Details | |
| 2024-11-04 01:35:22 -0600 | Rating Details | |
| 2024-11-04 01:11:20 -0600 | Rating Details | |
| 2024-11-03 23:46:15 -0600 | Rating Details | |
| 2024-11-03 23:09:33 -0600 | Rating Details | |
| 2024-11-03 22:58:09 -0600 | Rating Details | |
| 2024-11-03 21:03:09 -0600 | Rating Details | |
| 2024-11-03 21:02:49 -0600 | Rating Details | |
| 2024-11-03 20:05:52 -0600 | Rating Details | |
| 2024-11-03 18:57:37 -0600 | Rating Details | |
| 2024-11-03 18:43:37 -0600 | Rating Details | |
| 2024-11-03 17:29:33 -0600 | Rating Details | |
| 2024-11-03 17:13:42 -0600 | Rating Details | |
| 2024-11-03 16:57:09 -0600 | Rating Details | |
| 2024-11-04 18:52:58 -0600 | Rating Details | |
| 2024-11-04 18:50:08 -0600 | Rating Details | |
| 2024-11-04 12:30:50 -0600 | Rating Details | |
| 2024-11-04 03:37:35 -0600 | Rating Details | |
| 2024-11-03 22:53:23 -0600 | Rating Details | |
| 2024-11-03 22:24:41 -0600 | Rating Details | |
| 2024-11-03 22:06:20 -0600 | Rating Details | |
| 2024-11-03 21:58:47 -0600 | Rating Details | |
| 2024-11-03 20:29:41 -0600 | Rating Details | |
| 2024-11-03 20:13:09 -0600 | Rating Details | |
| 2024-11-03 20:09:19 -0600 | Rating Details | |
| 2024-11-03 19:56:00 -0600 | Rating Details | |
| 2024-11-03 19:45:11 -0600 | Rating Details | |
| 2024-11-03 19:13:37 -0600 | Rating Details | |
| 2024-11-03 18:37:54 -0600 | Rating Details | |
| 2024-11-03 18:27:05 -0600 | Rating Details | |
| 2024-11-03 16:37:38 -0600 | Rating Details | |
| 2024-11-03 15:47:17 -0600 | Rating Details | |
| 2024-11-03 14:37:25 -0600 | Rating Details | |
| 2024-11-03 13:17:01 -0600 | Rating Details | |
| 2024-11-03 11:53:46 -0600 | Rating Details | |
| 2024-11-03 11:29:23 -0600 | Rating Details |